Valneva SE (VALN) Restructuring Costs (2023 - 2024)
Valneva SE's (VALN) quarterly Restructuring Costs came in at -$1.0 million in Q2 2024, up 91.56% quarter-over-quarter from -$12.0 million in Q4 2023.
Valneva SE (VALN) Restructuring Costs (2023 - 2024) Analysis & Trends
Valneva SE has disclosed Restructuring Costs across 2 years of filings, most recently posting -$1.0 million for Q2 2024.
- Restructuring Costs for Q2 2024 came in at -$1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was -$1.0 million (changed N/A YoY), and the FY2023 annual result was -$12.0 million, changed N/A from the prior year.
- Restructuring Costs came in at -$1.0 million for Q2 2024 at Valneva SE, up from -$12.0 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of -$1.0 million in Q2 2024 to a low of -$12.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Valneva SE | 163.67 Mn | 40.43 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1.02 Mn |
| Dec 31, 2023 | -12.05 Mn |